TCA
IBB icon

Transcend Capital Advisors’s iShares Biotechnology ETF IBB Stock Holding History

Transcend Capital Advisors’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.4M Sell
12,643
-16
-0.1% -$2.75K 0.16% 113
2026
Q1 		$2.14M Sell
12,659
-708
-5% -$121K 0.17% 116
2025
Q4 		$2.26M Buy
13,367
+3,045
+30% +$495K 0.17% 118
2025
Q3 		$1.49M Buy
10,322
+1
+0% +$136 0.1% 177
2025
Q2 		$1.31M Sell
10,321
-664
-6% -$81.5K 0.1% 182
2025
Q1 		$1.4M Buy
10,985
+27
+0.2% +$3.66K 0.1% 206
2024
Q4 		$1.45M Buy
10,958
+92
+0.8% +$12.9K 0.1% 192
2024
Q3 		$1.58M Sell
10,866
-41
-0.4% -$5.93K 0.11% 200
2024
Q2 		$1.5M Sell
10,907
-83
-0.8% -$11.1K 0.11% 195
2024
Q1 		$1.51M Buy
10,990
+15
+0.1% +$2.05K 0.12% 178
2023
Q4 		$1.49M Buy
10,975
+497
+5% +$60.6K 0.13% 168
2023
Q3 		$1.28M Buy
10,478
+400
+4% +$50.9K 0.12% 170
2023
Q2 		$1.28M Buy
10,078
+5,839
+138% +$759K 0.12% 177
2023
Q1 		$548K Sell
4,239
-1,605
-27% -$210K 0.06% 275
2022
Q4 		$767K Buy
5,844
+409
+8% +$52.9K 0.08% 225
2022
Q3 		$636K Buy
5,435
+1,124
+26% +$140K 0.07% 247
2022
Q2 		$507K Sell
4,311
-6,114
-59% -$726K 0.05% 294
2022
Q1 		$1.36M Sell
10,425
-10
-0.1% -$1.3K 0.12% 179
2021
Q4 		$1.59M Buy
10,435
+36
+0.3% +$5.57K 0.14% 165
2021
Q3 		$1.66M Sell
10,399
-401
-4% -$67.5K 0.15% 151
2021
Q2 		$1.76M Buy
10,800
+3,103
+40% +$478K 0.25% 99
2021
Q1 		$1.16M Sell
7,697
-231
-3% -$36.7K 0.14% 163
2020
Q4 		$1.2M Sell
7,928
-718
-8% -$103K 0.16% 146
2020
Q3 		$1.17M Buy
+8,646
New +$1.17M 0.21% 101
2020
Q2 		– Sell
-3,258
Closed -$351K – 151
2020
Q1 		$351K Buy
+3,258
New +$375K 0.11% 164

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.9% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

Transcend Capital Advisors's IBB Position: Q2 2026 in Review

Transcend Capital Advisors reduced its iShares Biotechnology ETF (IBB) stake by 0.13% in Q2 2026, selling an estimated $2.75K and leaving 12,643 shares worth $2.4M. The position accounts for 0.16% of the portfolio, ranked #113.

Transcend Capital Advisors first reported a position in IBB in Q1 2020 and has held it in 25 quarters since. 960 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

  • Transcend Capital Advisors held 12,643 shares of iShares Biotechnology ETF worth $2.4M as of Q2 2026.
  • Transcend Capital Advisors sold 16 iShares Biotechnology ETF shares in Q2 2026, an estimated $2.75K.
  • iShares Biotechnology ETF made up 0.16% of Transcend Capital Advisors's portfolio in Q2 2026, its #113 holding.
  • Transcend Capital Advisors first reported a position in iShares Biotechnology ETF in Q1 2020 and has held it in 25 quarters since.
  • 960 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on Transcend Capital Advisors's 13F filing for Q2 2026, filed 4 Aug 2026.